BCG immunotherapy for recurrent malignant melanoma - A study of delayed hypersensitivity to recall antigens and relationship to prognosis

Shelley L. Rasmussen, Jordan U. Gutterman, Evan M Hersh, Sydney Boston, M. Marshall, Barry W. Brown

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of BCG treatment. Of these patients, those with less than five involved nodes had the longest disease-free interval and survival times. Patients who had increases in skin test reactivity generally showed these increases by the first visit after initiation of BCG therapy.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume10
Issue number1
DOIs
StatePublished - 1980
Externally publishedYes

Fingerprint

Delayed Hypersensitivity
Mycobacterium bovis
Immunotherapy
Melanoma
Antigens
Skin Tests
Disease-Free Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

BCG immunotherapy for recurrent malignant melanoma - A study of delayed hypersensitivity to recall antigens and relationship to prognosis. / Rasmussen, Shelley L.; Gutterman, Jordan U.; Hersh, Evan M; Boston, Sydney; Marshall, M.; Brown, Barry W.

In: Cancer Immunology, Immunotherapy, Vol. 10, No. 1, 1980, p. 17-26.

Research output: Contribution to journalArticle

Rasmussen, Shelley L. ; Gutterman, Jordan U. ; Hersh, Evan M ; Boston, Sydney ; Marshall, M. ; Brown, Barry W. / BCG immunotherapy for recurrent malignant melanoma - A study of delayed hypersensitivity to recall antigens and relationship to prognosis. In: Cancer Immunology, Immunotherapy. 1980 ; Vol. 10, No. 1. pp. 17-26.
@article{a4999ddbd5eb4603b74f8e22de7c6636,
title = "BCG immunotherapy for recurrent malignant melanoma - A study of delayed hypersensitivity to recall antigens and relationship to prognosis",
abstract = "A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of BCG treatment. Of these patients, those with less than five involved nodes had the longest disease-free interval and survival times. Patients who had increases in skin test reactivity generally showed these increases by the first visit after initiation of BCG therapy.",
author = "Rasmussen, {Shelley L.} and Gutterman, {Jordan U.} and Hersh, {Evan M} and Sydney Boston and M. Marshall and Brown, {Barry W.}",
year = "1980",
doi = "10.1007/BF00199274",
language = "English (US)",
volume = "10",
pages = "17--26",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - BCG immunotherapy for recurrent malignant melanoma - A study of delayed hypersensitivity to recall antigens and relationship to prognosis

AU - Rasmussen, Shelley L.

AU - Gutterman, Jordan U.

AU - Hersh, Evan M

AU - Boston, Sydney

AU - Marshall, M.

AU - Brown, Barry W.

PY - 1980

Y1 - 1980

N2 - A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of BCG treatment. Of these patients, those with less than five involved nodes had the longest disease-free interval and survival times. Patients who had increases in skin test reactivity generally showed these increases by the first visit after initiation of BCG therapy.

AB - A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of BCG treatment. Of these patients, those with less than five involved nodes had the longest disease-free interval and survival times. Patients who had increases in skin test reactivity generally showed these increases by the first visit after initiation of BCG therapy.

UR - http://www.scopus.com/inward/record.url?scp=0019171457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019171457&partnerID=8YFLogxK

U2 - 10.1007/BF00199274

DO - 10.1007/BF00199274

M3 - Article

VL - 10

SP - 17

EP - 26

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -